86
Participants
Start Date
September 1, 2016
Primary Completion Date
June 17, 2019
Study Completion Date
June 15, 2020
BXQ-350
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
University of Kentucky Markey Cancer Center, Lexington
The Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Barrett Center, Cincinnati
University of New Mexico Cancer Center, Albuquerque
Lead Sponsor
Collaborators (1)
CTI Clinical Trial and Consulting Services
OTHER
Bexion Pharmaceuticals, Inc.
INDUSTRY